NCT01824524View on ClinicalTrials.gov

A Pharmacokinetic and Safety Study of Osmotic Release Oral System (OROS) Hydromorphone in Non-Opioid Tolerant Chinese Participants With Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Pain
Interventions
DRUG

Hydromorphone

Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.

Trial Locations (2)

Unknown

Beijing

Changsha

All Listed Sponsors
lead

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

NCT01824524 - A Pharmacokinetic and Safety Study of Osmotic Release Oral System (OROS) Hydromorphone in Non-Opioid Tolerant Chinese Participants With Cancer | Biotech Hunter | Biotech Hunter